View Older Stories View More Recent Stories

Mar 16, 2025 08:08AM ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
Mar 15, 2025 08:30AM ROSEN, A LONGSTANDING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 12, 2025 04:16PM Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Mar 11, 2025 06:19PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 10, 2025 06:01PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 10, 2025 04:00PM NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Mar 7, 2025 10:52PM ROSEN, A TOP-RANKED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 6, 2025 04:45PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 4, 2025 08:06PM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 4, 2025 04:00PM NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Mar 4, 2025 11:08AM ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Mar 3, 2025 08:01PM ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 3, 2025 11:55AM Intellia Therapeutics (NTLA) PT Lowered to $50 at Truist Securities
Mar 2, 2025 02:15PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 1, 2025 02:15PM ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 1, 2025 07:56AM Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Feb 28, 2025 01:08PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 28, 2025 07:06AM Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to Sell
Feb 28, 2025 02:12AM JPMorgan Downgrades Intellia Therapeutics (NTLA) to Neutral
Feb 27, 2025 03:04PM Intellia Therapeutics (NTLA) PT Raised to $14 at Citi
Feb 27, 2025 07:30AM Intellia Therapeutics (NTLA) Tops Q4 EPS by 7c
Feb 26, 2025 06:15PM ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 26, 2025 04:00PM NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 25, 2025 06:10PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 25, 2025 11:16AM DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Feb 23, 2025 10:27PM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 22, 2025 10:23PM ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 20, 2025 05:11PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 20, 2025 04:00PM NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 18, 2025 06:42PM INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Feb 17, 2025 03:42PM ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 14, 2025 04:00PM NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Feb 14, 2025 10:53AM INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Jan 27, 2025 03:44AM Morgan Stanley Downgrades Intellia Therapeutics (NTLA) to Equalweight
Jan 22, 2025 07:31AM Intellia Therapeutics (NTLA) Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
Jan 13, 2025 07:42AM Intellia Therapeutics (NTLA) PT Lowered to $40 at Oppenheimer
Jan 10, 2025 10:13AM Intellia Therapeutics (NTLA) PT Lowered to $50 at BMO Capital; 'Strategic Plan Unsurprising, May Disappoint Investors'
Jan 10, 2025 05:43AM Intellia Therapeutics (NTLA) PT Lowered to $45 at BofA Securities
Nov 30, 2024 04:00AM Is Trump 2.0 good or bad for healthcare stocks?
Nov 25, 2024 07:30AM Intellia Therapeutics (NTLA) Announces FDA RMAT Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Nov 18, 2024 07:07AM Intellia Therapeutics (NTLA) Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z) May Favorably Impact Disease Progression in Transthyretin Amyloidosis
Nov 11, 2024 07:52AM Intellia Therapeutics (NTLA) PT Lowered to $60 at Oppenheimer
Nov 7, 2024 10:43AM Stifel Reiterates Buy Rating on Intellia Therapeutics (NTLA)
Nov 7, 2024 08:21AM Intellia Therapeutics (NTLA) Tops Q3 EPS by 5c
Oct 24, 2024 10:57AM BMO Capital Reiterates Outperform Rating on Intellia Therapeutics (NTLA)
Oct 24, 2024 09:43AM Intellia Therapeutics (NTLA) PT Lowered to $18 at Baird
Oct 24, 2024 08:01AM Intellia Therapeutics (NTLA) Presents Positive Results from the Phase 2 Study of NTLA-2002
Oct 16, 2024 07:54AM BMO Capital Reiterates Outperform Rating on Intellia Therapeutics (NTLA)
Oct 7, 2024 07:31AM Intellia Therapeutics (NTLA) Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
View More Recent Stories View Older Stories